The company is managed properly. For an investor, great value shall arise with the company approving Share Buy Backs in the AGM. There's a lot of upside but a minor hiccup with this current upcoming lockdown from 1st June to 14th June. Still a great opportunity to add more if the price comes down during this period.
I think Uchitec will stay at RM 3++ for quite a long time. This is a dividend share and you can expect dividend of RM 0.18 per share each year for the next 5 years. This dividend yield is almost 3x the current FD rate, so to have part of your money invested in this kind of stock for steady stream of cash flow is a good strategy to stabilize the entire investment portfolio while you allocate the rest of your money in more adventurous shares / business.
How sure are u? Did you attend the AGM? Have you read the AGM minutes? The pioneer status expire on 31st Dec 2022. They are planning to submit their application in 2nd Halt of this year. Please check first before you comment. TCLSS..... haiz,.
@ooihk899 - i did attend past 6yrs AGM and yes, i read the AR. fair price is RM2.7 if they do not get the Pioneer Status (because of unstable gomen and changes in policy) the profit margins will disappear in thin air. So then the rerated price is around RM1.7 thereabout. I am sure u know that there is no growth catalyst here. Did you read and understand the AR or not? knn
TKLSS, are you sure you know how to read??? Better go back to ABMB thread and curse there. Hahaha, Want to buy cheap, that's why talk ck here. Below are your comment. It sounds very sure they will not get the pioneer status and you didn't even mention about their planned application on the pioneer status. When wanted to write, please give a fair comment. I'll stop here.
'RM2.70 is fair value. Market will correct very soon. Next level of support (after expiry of pioneer status) is RM1.70 Look and see. This were the support levels in past 18months.'
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....